These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12049885)

  • 1. How tainted is medicine?
    Vento S
    Lancet; 2002 May; 359(9319):1775. PubMed ID: 12049885
    [No Abstract]   [Full Text] [Related]  

  • 2. Science, medicine and... the markets.
    Pawlotsky JM
    J Hepatol; 2006 Sep; 45(3):341-2. PubMed ID: 16854496
    [No Abstract]   [Full Text] [Related]  

  • 3. Just how tainted has medicine become?
    Lancet; 2002 Apr; 359(9313):1167. PubMed ID: 11955529
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomedical research and insider trading.
    Ferguson JR
    N Engl J Med; 1997 Aug; 337(9):631-4. PubMed ID: 9271488
    [No Abstract]   [Full Text] [Related]  

  • 5. American Psychiatric Association says no to industry funding for symposiums.
    Tanne JH
    BMJ; 2009 Apr; 338():b1426. PubMed ID: 19349347
    [No Abstract]   [Full Text] [Related]  

  • 6. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Congresses, meetings and events. Which route do we take?].
    González González J
    Semergen; 2014 Oct; 40(7):410. PubMed ID: 24837527
    [No Abstract]   [Full Text] [Related]  

  • 8. How tainted is medicine?
    Wheatley D
    Lancet; 2002 May; 359(9319):1775-6. PubMed ID: 12049887
    [No Abstract]   [Full Text] [Related]  

  • 9. Industry sponsorship of scientific meetings: peaks and troughs.
    Isaacs D
    J Paediatr Child Health; 2012 Jul; 48(7):547. PubMed ID: 22758896
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmaceutical industry--to whom is it accountable?
    Jacobs C
    N Engl J Med; 2000 Nov; 343(19):1416-7; discussion 1417. PubMed ID: 11183878
    [No Abstract]   [Full Text] [Related]  

  • 11. GAO report says drug R & D costs rising, innovation decreasing.
    Consult Pharm; 2007 Mar; 22(3):257-8. PubMed ID: 17691159
    [No Abstract]   [Full Text] [Related]  

  • 12. Hotel-based medicine.
    Greenwald R
    J Rheumatol; 2009 Feb; 36(2):456; author reply 456-7. PubMed ID: 19208583
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidemiology and profit for pharmaceutical companies.
    James PB; Crombie IK
    Lancet; 2002 May; 359(9317):1621. PubMed ID: 12048000
    [No Abstract]   [Full Text] [Related]  

  • 14. [Reaction to "About the comparison of public-private cooperation"].
    Rübsaam J
    Tijdschr Psychiatr; 2006; 48(4):343; author reply 343-4. PubMed ID: 16956001
    [No Abstract]   [Full Text] [Related]  

  • 15. Italian drug firms rethink ban on conference support.
    Feder T
    Nature; 1994 Dec; 372(6505):392. PubMed ID: 7984223
    [No Abstract]   [Full Text] [Related]  

  • 16. The challenge of life. Biomedical progress and human values. Roche anniversary symposium. Introduction to the symposium--an outline of its scope and limitations.
    Todd L
    Experientia Suppl; 1972; 17():29-32. PubMed ID: 4644544
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug development costs are overstated by the industry].
    Jeppsson A
    Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545
    [No Abstract]   [Full Text] [Related]  

  • 18. Harbinger for the era of personalized medicine?
    Tracey WR
    Mol Interv; 2005 Aug; 5(4):200; author reply 200. PubMed ID: 16123532
    [No Abstract]   [Full Text] [Related]  

  • 19. How tainted is medicine?
    Davies P; Jenkinson S
    Lancet; 2002 May; 359(9319):1775. PubMed ID: 12049886
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug price deal spells windfall for researchers.
    Bosch X
    Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.